Physician profile
Thai Nguyen
NPI 1669555140
$1,759.55
in general payments reported to CMS, 2019-2025
21 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $116 · 2021: $225 · 2022: $306 · 2023: $222 · 2024: $343 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $403.67 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $176.33 | 2019-2023 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $170.87 | 2019-2023 | Farxiga |
| Amgen INC. | $142.97 | 2019-2025 | Krystexxa, Tavneos |
| Aurinia Pharma U.S., INC. | $136.98 | 2021-2024 | Lupkynis |
| Akebia Therapeutics INC | $115.85 | 2019-2025 | Vafseo |
| Sumitomo Pharma America, INC. | $95.30 | 2024 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $88.62 | 2019-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $79.95 | 2021-2023 | |
| Vifor Pharma, INC. | $54.42 | 2019-2023 | Veltassa |
| Travere Therapeutics, INC. | $54.24 | 2022-2023 | |
| Horizon Therapeutics Plc | $47.57 | 2022 | |
| Glaxosmithkline, LLC. | $33.73 | 2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $28.61 | 2019 | |
| Abbott Laboratories | $23.30 | 2024 | Proclaim |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.26 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $21.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2020 | |
| Amneal Pharmaceuticals LLC | $18.24 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.92 | 2019 | |
| Livanova USA, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thai Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.